Cynata Therapeutics Limited (ASX:CYP)

Market Cap	2.68M -94.2%
Revenue (ttm)	1.71M -9.2%
Net Income	-9.09M
EPS	-0.04
Shares Out	243.45M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	171,499
Open	0.0110
Previous Close	0.0110
Day's Range	0.0110 - 0.0110
52-Week Range	0.0100 - 0.4350
Beta	1.09
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 26, 2026

About Cynata Therapeutics

Cynata Therapeutics Limited, together with its subsidiaries, engages in the development and commercialization of proprietary induced pluripotent stem cell and mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. The company’s lead therapeutic product candidate is CYP-001, which has completed Phase 2 clinical trial for the treatment of graft versus host disease. It is also involved in the development of CYP-004, which is in Phase 3 clinical trial used for the treatment of osteoarthritis; CYP-006TK, a n...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2003
• Employees: 2
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: CYP

Financial Performance

In fiscal year 2026, Cynata Therapeutics's revenue was 1.71 million, a decrease of -9.20% compared to the previous year's 1.89 million. Losses were -9.09 million, -3.21% less than in 2025.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 18, 2026

Data Sources Report a data error